Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12357693-B2
Publication Date
2025-07-15
Expiration Date
Abstract
Methods for treating cancer and/or inducing tumor regression in mammals (e.g., humans) by increasing the metabolism of the mammal, administering a BA dye to the mammal, and thereafter exposing the tumor to actinic light for activation of the BA dye.
Core Innovation
The invention relates to treating a malignant brain tumor in a subject by combining metabolism-altering enhancement of benzophenoxazinium/benzophenothiazinium/benzophenoselenazinium (BA) based photodynamic therapy (BA-PDT) with an EtNBS compound followed by exposure to actinic light. The approach is described as counterintuitive “metabolism-altering” enhancement of BA-PDT for tumor regression.
The problem being solved is that BA-based photodynamic therapy is used to treat tumors, and the disclosed method aims to improve anti-tumor effect and tumor regression outcomes by altering subject and/or tumor metabolism prior to light activation. The background/problem context provided in the partial content is framed as improving tumor regression when BA-PDT is used.
The method includes administering at least one of glucose, glucagon, corticosteroids, growth hormones, thyroid hormones and insulin until the plasma glucose level is above the basal plasma glucose level, administering at least one EtNBS compound, and thereafter exposing the subject to actinic light. The disclosed implementation is directed to malignant brain tumor treatment, and the light exposure is described as activating the BA dye/EtNBS with actinic light.
Claims Coverage
The independent claim contains three sequential inventive steps that define the treatment of a malignant brain tumor: elevating plasma glucose above basal using specified glucose-related agents, administering EtNBS, and thereafter exposing the subject to actinic light. The inventive features are implemented with additional dependently refined details in subordinate claims.
Glucose elevation above basal plasma glucose
Administering at least one of glucose, glucagon, corticosteroids, growth hormones, thyroid hormones and insulin to the subject until the plasma glucose level of the subject is above the basal plasma glucose of the subject.
Administration of an EtNBS compound
Administering at least one EtNBS compound to the subject.
Actinic light exposure thereafter
Thereafter exposing the subject to actinic light.
The claim coverage centers on a treatment sequence for a malignant brain tumor that first raises plasma glucose above basal using specified agents, then administers an EtNBS compound, and then exposes the subject to actinic light. Dependent claims further narrow the tumor subtype and refine the EtNBS identity and light-energy/timing constraints as stated in the claim set provided.
Stated Advantages
Improved tumor regression compared with BA-PDT alone, including substantially greater tumor volume reduction and increased eradication when metabolism elevation is combined with BA-PDT versus BA-PDT alone [stated in partial content].
Increased effectiveness of MetabBA-PDT when metabolism elevation is combined with BA-PDT, including when metabolic elevation is achieved through combinations such as glucose+insulin or lipid/FFA, or insulin alone [stated in partial content].
Documented Applications
Treating a malignant brain tumor in a subject using glucose-elevation prior to EtNBS administration followed by actinic light exposure [grounded in independent claim].
Treating malignant brain tumor where the malignant tumor is a glioma [dependent claim].
In vivo tumor regression studies are described for hamster pancreatic and rat bladder/brain tumor models [documented in partial content summary].
Interested in licensing this patent?